Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Evidence-Based Dermatology: Research Commentary
June 2000

Biologic Treatment of Basal Cell Carcinoma

Author Affiliations

Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

Arch Dermatol. 2000;136(6):774-775. doi:10.1001/archderm.136.6.774

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamBeutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens MLJ Am Acad Dematol. 1999;41:1002-1007

The incidence of basal cell carcinomas (BCCs) is very high. Despite the effectiveness of surgical treatments, the development of effective biologic therapies for BCC is important.1 Beutner et al2 performed a randomized, double-blind pilot trial evaluating the safety and efficacy of imiquimod 5% cream vs vehicle in the treatment of BCCs.

First Page Preview View Large
First page PDF preview
First page PDF preview